The primers used for HPMCs were as follows: HIF-1α, F: ACT GCA CAG GCC ACA TTC ACG, R: AAT CAG CAC CAA GCA GGT CAT AGG; SGLT2, F: GCT GGA ... with protease and phosphatase inhibitors. Lysates were ...

Note: CAR, chimeric antigen receptor; NLRP3: nod-like receptor protein three; RAAS: renin-angiotensin-aldosterone system; SGLT2-i: sodium-glucose cotransporter-2 inhibitor; TGF-β: transforming growth ...

SGLT2 inhibitors were associated with better cardioprotective effects among older adults than younger adults with type 2 diabetes.

If validated prospectively, the findings could be ‘transformative’ for patients with no current medical options.

Less than 5% of hospitalized adults with type 2 diabetes received an SGLT2 inhibitor or GLP-1 before being discharged, ...

For the first time, researchers said SGLT2 inhibitors may have some disease-modifying potential for nonsevere aortic stenosis ...

A recent review shows who newer medications for type 2 diabetes may help the most, particularly in reducing the risk of ...

SGLT-2 inhibitors canagliflozin, empagliflozin, and dapagliflozin showed overall comparable effectiveness on cardiovascular outcomes in T2D.

SGLT-2 inhibitors, compared with DPP-4 inhibitors, were associated with a lower risk for liver cirrhosis among patients with type 2 diabetes. Sodium-glucose cotransporter 2 (SGLT-2) inhibitors ...

placebo. Perspective from Shannon C. Scott, DO, FACOFP Use of a sodium-glucose cotransporter 2, or SGLT2, inhibitor combined with calorie restriction resulted in greater rates of type 2 diabetes ...

sodium-glucose transporter 2 (SGLT2) inhibitors — these reduce the amount of glucose reabsorbed by the kidneys, meaning that it is excreted in the urine. A meta-analysis, published in the ...